Precision BioSciences Missed Consensus Estimates
Thursday, May 15, 2025 at 7:01 AM ET
Precision BioSciences (DTIL) reported a loss of $2.21 per share on revenue of $0.03 million for the first quarter ended March 2025. The consensus estimate was a loss of $0.43 per share on revenue of $10.00 million. The company missed consensus estimates by 413.95% while revenue fell 99.84% compared to the same quarter a year ago.
Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly specific and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind.
Earnings Whisper Grade
Power Rating
-
-
Reported Earnings
$-2.21
Earnings Whisper®
-
Consensus Estimate
$-0.43
Earnings Surprise
Earnings Growth
Reported Revenue
$29.00 Thou
Revenue Estimate
$10.00 Mil
Revenue Surprise
Revenue Growth